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Abstract 
Background: There is no approved treatment for primary progressive multiple sclerosis (PPMS). 
Fingolimod, an oral sphingosine 1-phosphate receptor modulator, has significant benefits in relapsing 
MS (RMS), but has not been assessed in PPMS. 
Methods: This randomised, double-blind trial (ClinicalTrials.gov, NCT00731692) evaluated fingolimod 
0.5 mg versus placebo on disability progression in patients with PPMS treated for at least 3 years. Key 
inclusion criteria: clinical diagnosis of PPMS; disease duration 2–10 years and objective evidence of 
disability progression in the previous 2 years. A novel primary composite endpoint, based on change 
from baseline in Expanded Disability Status Scale (EDSS), 25’ Timed-Walk Test or 9-Hole Peg Test, was 
used to assess time to 3-month confirmed disability progression (3M-CDP). Key secondary endpoints: 
disability progression assessed by EDSS and percent brain volume change (PBVC).  
Findings: The efficacy analysis set (N=823) comprised 336 and 487 patients randomised to fingolimod 
0.5 mg and placebo, respectively. Baseline characteristics were similar across groups and representative 
of a progressive population (48.4% women; mean age 48.5±8.4 years, mean EDSS=4.67±1.03, 87% free 
of Gadolinium-enhancing lesions). By end of the study, 3M-CDP (composite primary endpoint; Kaplan-
Meier estimate, 95% confidence interval) occurred in 77.2% (71.87%; 82.51%) versus 80.3% (73.31%; 
87.25%) of fingolimod versus placebo patients. Neither the primary composite (risk reduction [RR] 
5.05%; p=0.544), nor EDSS (RR 11.99%; p=0.217) endpoints were met. PBVC was not different between 
the fingolimod and placebo groups (‒1.49 and ‒1.53; p=0.673). There were fewer Gd+ and new T2 
lesions in the fingolimod arm (78% and 73% reduction; both p<0.001), although overall MRI lesion 
activity was low. Safety results were generally consistent with fingolimod RMS trials. 
Interpretation: The anti-inflammatory effects of fingolimod did not slow disease progression or brain 
volume loss in PPMS. Therapeutic strategies for PPMS may require different approaches than utilised for 
RMS. 
Funding: Novartis Pharma AG (Word count: 300 [limit 300]) 
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Panel: Research in context 
Systematic review 
We searched PubMed on July 8, 2015, with no restriction on language or publication date, using the 
search term “primary progressive multiple sclerosis”. We identified 324 articles, of which 4 were 
primary reports of results from randomised, blinded, placebo-controlled clinical trials. Of these, 2 were 
large-scale, phase III trials: the PROMiSE trial, in which the active comparator was glatiramer acetate, 
was designed as a 3-year trial, but was terminated early; and the 2-year OLYMPUS trial in which 
rituximab was the active comparator. Both studies used the EDSS as the primary outcome measure and 
were negative in terms of a treatment benefit on disability progression and BVL, despite effects on some 
MRI parameters. Subsequent discussion on these studies included the influence of the patient 
populations recruited, the duration,30 and the endpoints used on the ability of PPMS trials to detect 
treatment differences.  
 
Interpretation  
INFORMS addressed the important limitations of previous studies in PPMS. INFORMS was adequately 
designed with a novel composite endpoint and patients were exposed to study drug for at least 3 years. 
Furthermore, the study was powered to 90% for the detection of a clinically meaningful treatment 
effect on disability progression. INFORMS successfully recruited a primary progressive MS population 
with very low inflammatory activity (few relapses and low number of Gd-enhancing lesions at baseline 
and throughout the study). Despite the adequate design and a worsening trial population, INFORMS did 
not show a benefit for fingolimod versus placebo in terms of disability progression or BVL in patients 
with PPMS. Furthermore, the finding that the pharmacodynamic  effects of fingolimod did not impact 
disability progression or BVL, despite effects on MRI-detected inflammatory lesion activity that were 
consistent with results in RMS, add to the important discussion on the pathophysiology of progressive 
phase MS and will guide future research. 
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Introduction 
Multiple sclerosis (MS) is a chronic, autoimmune and neurodegenerative disorder of the central nervous 
system (CNS).1 While relapsing MS (RMS, encompassing relapsing-remitting and secondary progressive 
MS) is the most frequent form, 10‒15% of MS patients exhibit a progressive disability from onset with 
no, or very infrequent superimposed relapses and remissions (primary progressive MS or PPMS).2,3  
Although part of the MS disease spectrum,4 PPMS differs from RMS in several ways. The inflammatory 
component, as measured by the development of gadolinium (Gd)-enhancing MRI lesions, is less 
prominent than in RMS.2,5-Men and women are equally affected, in contrast to the higher frequency of 
women in RMS.3,6 Patients with PPMS are generally about 10 years older at diagnosis compared with 
RMS patients (mean age around 40 years for PPMS versus 30 years for RMS).2,6 Moreover, disability 
progresses more rapidly in PPMS such that the severity of disability according to age is similar to that in 
RMS.7  
Despite the range of effective options available for RMS, to date, no treatment has been shown to 
change the disease course in PPMS. 8,9 Fingolimod (FTY720; GILENYATM, Novartis Pharma AG, Basel, 
Switzerland) is an oral sphingosine 1-phosphate (S1P) receptor modulator that, by downregulation of 
the S1P1 receptor subtype, prevents lymphocyte egress from lymphoid tissues into the circulation. In 
RMS, fingolimod reduces the frequency of relapses, delays disability progression and reduces magnetic 
resonance imaging (MRI) lesion activity versus placebo; and decreases the frequency of relapses and 
active MRI lesions versus interferon (IFN) β-1a IM.10-12 Furthermore, fingolimod significantly limits brain 
volume loss (BVL) in RMS compared with both placebo and IFN-β1a IM12,13, a measure that correlates 
with disability progression.14,15  
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In addition to preventing lymphocyte egress from lymphoid tissues, fingolimod can cross the 
blood‒brain barrier and bind to S1P1, S1P3, and S1P5 receptors located on neural cells.16  Therefore, 
part of its therapeutic action may be independent of its effect on peripheral macrophages. It is known 
that S1P1 and S1P3 receptors are strongly expressed within MS lesions and this expression has been 
associated with astrogliosis, a key pathological feature of MS lesions.17 In vitro and in vivo data suggest 
that fingolimod can directly inhibit neurodegeneration. Fingolimod treatment of isolated human 
astrocytes desensitised the S1P receptor-mediated neuroinflammatory pathways resulting in reduced 
astrogliosis and neurodegeneration.17 Animal models of MS have demonstrated that fingolimod 
treatment can result in reduced neuroinflammatory disease and improved CNS tissue integrity.18,19 This 
ability of fingolimod to reduce inflammatory infiltrates into the CNS, coupled with the potential effects 
on intrinsic mechanisms within the brain resulting in reduced neurodegeneration, provided the rationale 
for the INvestigating FTY720 ORal in Primary Progressive MS (INFORMS) trial (NCT00731692). In this 
study, a novel composite endpoint was devised, including the 25’ Timed Walk Test (25’TWT)20 and the 
Nine-Hole Peg Test (9-HPT)20,21 as additional components to the expanded disability status scale 
(EDSS),22 to provide a more sensitive and comprehensive assessment of disability than the EDSS alone.  
Methods 
Study Design  
This multicentre, double-blind, placebo-controlled, parallel-group study was conducted in accordance 
with the International Conference on Harmonization Guidelines for Good Clinical Practice23 and the 
Declaration of Helsinki.24 The protocol was approved by each site’s institutional review board; patients 
gave written informed consent. A Steering Committee (for membership see the Supplementary 
Appendix) oversaw the study. 
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Randomization and masking 
The randomization sequence was automatically generated by a validated system under the 
responsibility of Novartis Drug Supply Management. The randomization occurred in blocks of 4 within 
centre in a 1:1 ratio to fingolimod or placebo. All randomised drug assignments remained blinded for the 
entire double-blind treatment period. Treatment codes were accessible only to members of the data 
and safety monitoring board (DSMB) which was independent of Novartis and not otherwise involved in 
the conduct of the study. Masking (blinding) was achieved by using identical packaging, and identical 
capsule colour and size for active treatment and placebo. 
Patients were initially randomised to receive fingolimod 1.25 mg/day or matching placebo in a 1:1 ratio. 
Following a 2009 protocol amendment after the decision to select the 0.5 mg dose of fingolimod for 
submission to regulatory authorities for RMS and to discontinue development of fingolimod 1.25 mg 
randomization into this initial cohort of patients was stopped. Patients randomised up to the release of 
this amendment were labelled as ‘Cohort 1’ with those originally randomised to fingolimod 1.25 mg 
switched in a blinded fashion to fingolimod 0.5 mg and those on placebo continued on matching 
placebo. 
From this time point in 2009 onwards, patients were randomised into a new cohort (‘Cohort 2’), which 
included patients who were recruited after the release of the amendment and were randomised in a 1:1 
ratio to receive fingolimod 0.5 mg/day or placebo.  
Heart rate reduction is a known pharmacologic effect of fingolimod that can potentially unblind study 
participants. To maintain blinding, an independent first dose administrator performed pulse rate 
monitoring after the first dose of study drug. Employees of the sponsor who were independent of the 
study team monitored first dose safety in a blinded fashion.  
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Patients 
Key eligibility criteria were age of 25‒65 years with a clinical diagnosis of PPMS according to the 2005 
revised McDonald criteria.25 Patients had to have demonstrated ≥1 year of disease progression plus two 
of the following three criteria: positive brain MRI; positive spinal cord MRI and/or positive cerebrospinal 
fluid (CSF). Central review to confirm that the diagnostic criteria for PPMS were met was required for all 
patients prior to randomization. 
Additional inclusion criteria included time from first reported symptoms of 2–10 years prior to study 
entry; evidence of disability progression documented by an increase in the EDSS score ≥0.5 points in the 
past 2 years; objective evidence of disability measured by EDSS score of 3.5‒6;  pyramidal functional 
system score ≥2; and a 25’TWT <30 seconds was required. Exclusion criteria were similar to previous 
RMS trials (for complete details, see Supplementary Appendix).10-12 
Study Procedures  
Clinical assessments were performed at screening and at randomization (baseline) and at study visits 
that included safety assessments at 2 weeks and 1, 2, 3, 6, 9, 12 months during the first year after 
randomization and then every 3 months until month 36. 
All efficacy assessments were performed by an independent specially trained and certified26 evaluating 
physician. MRI scans were analysed at a central MRI centre by trained staff blinded to the study-group 
assignments. EDSS assessments were scheduled at screening, baseline and then every 3 months during 
the double-blind treatment period, at the end of treatment and at the 3-month follow-up visit. In the 
case of MS relapse, EDSS assessment by the independent physician was required at an unscheduled visit 
to confirm relapse. The 25’TWT and 9-HPT were assessed at baseline and every 3 months throughout 
the double-blind treatment period, at the end of treatment and at the 3-month follow-up visit.  
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Specifications of the adverse event (AE) monitoring procedure, as defined in the study protocol, are 
detailed in the Supplementary Appendix, which also provides other methodologic details, the list of 
members of the independent DSMB, and the members of the independent diagnosis adjudication board. 
Objectives and End Points 
The primary objective was to evaluate the effect of fingolimod versus placebo on delaying the time to 
confirmed disability progression (CDP). CDP was defined as the first occurrence of a progression 
according to at least one of the following 3 criteria: increase from baseline in the EDSS score by 1 point 
in patients with baseline EDSS score ≤5.0 or 0.5 point in patients with baseline EDSS score ≥5.5; increase 
of at least 20% from baseline in the 25’TWT; increase of at least 20% from baseline in time taken to 
complete the 9-HPT. Progression in at least one of the three components had to be sustained and 
confirmed at least 3 months later at a scheduled visit. 
Protocol-defined key secondary objectives: 1) effect of fingolimod 0.5 mg versus placebo on delaying the 
time to 3-month CDP as measured by the EDSS; 2) effect of fingolimod 0.5 mg versus placebo on percent 
brain volume change (PBVC) as a measure of BVL. PBVC was measured using SIENA applied to T1-
weighted images.27 
Statistical Analysis 
The study was powered to 90% to detect a reduction between fingolimod and placebo in the time to 3-
month CDP based on the composite endpoint in a log-rank test at a two-sided significance level of 5%: a 
sample size of 654 patients (327 in each group) was needed to detect a 3-year event rate reduction in 
the fingolimod 0.5 mg group of 25% (50% event rate on placebo versus 37.5% on fingolimod).  
The primary efficacy analysis population comprised all patients randomised to fingolimod 0.5 mg or 
placebo (Cohort 2) and all patients randomised to placebo in Cohort 1. Patients had to have taken at 
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least one dose of study drug to be included (modified ITT principle). The decision to use the placebo 
patients from Cohort 1 in the primary analysis population was made after a blinded review of the 
baseline data that revealed no apparent differences between patients in Cohort 1 and 2. Cohort 1 and 2 
were also analysed separately (see Supplementary Appendix). All efficacy results, unless otherwise 
specified, are based on the primary efficacy analysis set. The safety analysis population comprised all 
patients from Cohorts 1 and 2. 
The primary analysis used a Cox proportional hazards model to test for differences between fingolimod 
and placebo in the time to 3-month CDP based on the composite endpoint, with region, age, baseline 
EDSS, baseline 25’TWT and baseline 9-HPT as covariates. 
The key secondary analysis of time to 3-month CDP based on EDSS was performed as for the primary 
efficacy endpoint, but only disability progressions based on the EDSS were analysed and baseline 
25’TWT and baseline 9-HPT were not included as covariates in the Cox proportional hazards model. 
PBVC was analysed using a random coefficients model including treatment and region as fixed effects, 
and time, number of Gd-enhancing lesions at baseline, baseline T2 lesion volume and normalised brain 
volume at baseline as continuous covariates. 
To control the type-I error rate, the primary and key secondary efficacy hypotheses were tested in 
sequential order in a hierarchical step down procedure.  
Role of the funding source 
The study sponsor participated in the design of the study, conduct of the study, data collection, data 
management, data analysis and interpretation, and preparation, review and approval of the paper. All 
authors had access to the data. All authors, including those employed by Novartis, were involved in 
manuscript preparation and had control over the content, for which they take full responsibility and 
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have given final approval for submission for publication.
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Results 
Enrolment was between July 2008 and August 2011. Patients were accrued across 148 centres in 18 
countries (see the Supplementary Appendix for a list of the centres and principal investigators). In total, 
1520 patients were screened with 970 randomised (280 patients were randomised (1:1) to fingolimod 
1.25 mg or placebo in Cohort 1 and 690 patients were randomised (1:1) to receive either fingolimod 0.5 
mg or placebo in Cohort 2). 
Patient disposition is summarised in Figure 1. Table 1 presents the baseline characteristics of the efficacy 
analysis set, which were similar across treatment groups (Supplementary Appendix presents the 
baseline characteristics for the entire INFORMS patient population [Cohorts 1 and 2]).   
The composite primary efficacy endpoint was not met (Table 2, Figure 2A): fingolimod demonstrated no 
difference compared with placebo (p=0.544) in the time to 3-month CDP. There was also no difference 
in the time to 3-month CDP based on EDSS alone (Table 2, Figure 2B). Efficacy by Cohort is presented in 
the Supplementary Appendix. No significant treatment effect was observed in either cohort. 
A similar analysis for 6-month CDP was conducted and the conclusions were consistent with that of the 
primary endpoint (data not shown). Subgroup analyses by sex, age (≤40 vs. 41‒55 vs. >55 years), EDSS at 
baseline (≤5 vs. >5), Gd lesion status at baseline and age/Gd status at baseline (≤50 and Gd+ ≥1 vs. >50 
and Gd+ < 1) yielded similar results and did not alter the conclusion of a lack of efficacy of fingolimod in 
patients with PPMS (data not shown).  
PBVC was also similar in patients treated with fingolimod 0.5 mg compared with placebo  
(Table 2). However, fingolimod reduced the number of new/newly enlarging T2 lesions by 73% and of 
Gd-enhancing T1 lesions by 78% (Table 2). A majority of patients remained free of new/newly enlarging 
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T2 lesions through the end of the study in both treatment arms (mean number of new/newly enlarging 
T2 lesions of 0.5 versus 0.13 lesions per year in the placebo and fingolimod arms, respectively; Table 2).  
Confirmed relapses were reported for 6 (1.8%) and 41 (8.4%) patients in the fingolimod 0.5 mg and 
placebo groups, respectively. 
As shown in Table 3, the incidence of AEs in the efficacy analysis set was generally comparable between 
groups (Supplementary Appendix provides a summary of AEs for the entire safety analysis set) and the 
overall AE profile was similar to trials of fingolimod for RMS.10,12 The events were mild or moderate in 
severity in 74.1% of those receiving fingolimod versus 75.2% for placebo. 
AEs that led to discontinuation of the study medication (including abnormal laboratory test results) were 
more common with fingolimod than with placebo (Table 3). Serious AEs were reported for 25.0% in 
patients receiving fingolimod and 24.0% for placebo.  
Five deaths occurred during the study. Two in the group originally randomised to fingolimod 1.25 mg 
(1.4%; single cases of respiratory tract infection and aspiration pneumonia); 1 (0.3%) randomised to 
fingolimod 0.5 mg in the efficacy analysis set (metastatic lung cancer); and 2 (0.4%) in the combined 
placebo group (single cases of convulsion and pulmonary embolism).  
AEs of special interest, such as cardiac conduction abnormalities, macular oedema, infections and 
neoplasms were in keeping with previous observations from RMS trials.   
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Discussion  
In PPMS patients, fingolimod treatment did not decrease the risk of progression of disability versus 
placebo. There was also no difference between fingolimod and placebo on BVL. In both treatment 
groups, BVL was approximately 0.5% per year and the majority of patients progressed in their disability 
status, irrespective of treatment. The effects of fingolimod on MRI measures of lesion activity and 
clinical relapses (although very few in number) were consistent with results from RMS studies.10-12  
INFORMS is the first large, prospective MS study that used a composite of three major domains of MS-
associated disability as the primary endpoint. This composite endpoint yielded more progression events 
than its components of which the highest event rate was recorded for the 25’TWT. The outcomes of all 
measures included were consistent, supporting the potential usefulness of the composite endpoint in 
future PPMS trials.   
Despite the inclusion of patients with a higher age and more advanced disability, the safety and 
tolerability results for fingolimod 0.5 mg in INFORMS were in keeping with RMS trials, including the rates 
of AEs of special interest such as cardiac conduction at first dose and infections. 
Based on the event rates of both the composite primary disability endpoint and its components, 
including the traditional EDSS endpoint, the study was adequately powered to detect a treatment effect. 
The trial recruited a large, well-defined worsening population of PPMS patients who progressed 
substantially during the course of the study. A total of 80% of placebo treated patients demonstrated 
CDP according to the primary composite and 59% according to the EDSS endpoint. Event rates according 
to the EDSS were higher than those observed in the placebo arms of two other large phase III trials. In 
PROMiSe,9 in which the active comparator was glatiramer acetate, the placebo arm event rate was 
45.2%, while in the OLYMPUS rituximab trial,8 the placebo rate was 38.5%. Interestingly more than 30% 
of the CDP events by the primary outcome occurred within the first 26 weeks after randomization. In 
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line with most previous PPMS cohorts,8,9 the INFORMS population showed a low rate of active 
inflammatory MRI lesions (<15% positive for Gd-enhancing lesions at baseline) and a moderate T2 lesion 
burden. Together, these data suggest that the inclusion criteria of INFORMS succeeded in recruiting a 
characteristic progressing PPMS population.4  
The rate of discontinuations in INFORMS was in line with previous PPMS trials,8,9 which were of shorter 
duration, and also consistent with fingolimod trials in RMS where an approximate attrition rate of 10% 
per annum was observed.10-12 Indeed, this rate of attrition was factored into the sample size calculations 
to ensure an ability to detect a treatment difference at the end of the trial. 
As with RMS, the rate of BVL in these PPMS patients substantially exceeded that observed in individuals 
without MS.28 In RMS, fingolimod showed a consistent and robust effect on BVL 12,13 that was not seen in 
this PPMS trial. In RMS the effect of fingolimod on BVL is associated with a reduction in inflammatory 
Gd-enhancing and new/enlarging T2 lesions, 15,29 but has also been attributed to additional actions 
independent of its anti-inflammatory effects. In PPMS, the effect of fingolimod on lesion activity (Gd-
enhancing and new/enlarging T2 lesions) was consistent with that seen in RMS, although relatively 
fewer PPMS patients had lesion activity (Gd-enhancing or new/newly enlarging T2 lesions). These 
observations suggest that although fingolimod has an impact on inflammatory disease activity, it had 
little effect on the process that leads to BVL and disability progression in PPMS. Similarly, in the 
PROMiSe and the OLYMPUS trial, there was no effect of the active compound on BVL despite an effect 
on Gd-enhancing activity and T2 lesion burden at some timepoints.8,9 
Unlike RMS, the inflammatory infiltrate within the CNS is not only less prominent in PPMS but also 
differs in its cellular composition.2,5 It is probable that the pathophysiologic mechanisms that drive BVL 
differ, at least partially, in these two MS phenotypes and neurodegenerative processes may play a more 
prominent role in PPMS. The results of INFORMS suggest that anti-neuroinflammatory strategies 
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currently applied in RMS are unlikely to be beneficial in PPMS, and that novel approaches may be 
required to treat patients with PPMS. 
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Table 1. Baseline characteristics of the patients, according to study group 
Characteristic 
Fingolimod 0.5 mg 
(N=336) 
Placebo 
(N=487) 
Total 
(N=823) 
Demographics 
Sex, n (%) 
Male 173 (51.5%) 252 (51.7%) 425 (51.6%) 
Female 163 (48.5%) 235 (48.3%) 398 (48.4%) 
Age (years)    
Median (range) 49.0 (24, 65) 49.0 (27, 65) 49.0 (24, 65) 
Mean (SD) 48.5 (8.6) 48.5 (8.3) 48.5 (8.4) 
Age distribution (years), n (%) 
18–30  6 (1.8%) 4 (0.8%) 10 (1.2%) 
31–40  60 (17.9%) 90 (18.5%) 150 (18.2%) 
41–50  127 (37.8%) 194 (39.8%) 321 (39.0%) 
>50 143 (42.6%) 199 (40.9%) 342 (41.6%) 
Race, n (%)    
Caucasian 324 (96.4%) 467 (95.9%) 791 (96.1%) 
Black 7 (2.1%) 6 (1.2%) 13 (1.6%) 
Asian 0 (0%) 4 (0.8%) 4 (0.5%) 
Other 5 (1.5%) 10 (2.1%) 15 (1.8%) 
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Clinical characteristics  
Disease duration since diagnosis, years 
Mean (SD) 2.80 (2.6) 2.91 (2.3) 2.87 (2.4) 
Median (range) 1.98 (0.1, 20.1) 2.35 (0.1, 10.4) 2.14 (0.1, 20.1) 
Disease duration  since onset of symptoms , years 
Mean (SD) 5.8 (2.5) 5.9 (2.4) 5.8 (2.4) 
Median (range) 5.4 (1, 20) 5.7 (2, 15) 5.6 (1, 20) 
EDSS score 
Mean (SD) 4.70 (1.03) 4.66 (1.03) 4.67 (1.03) 
Median (range) 4.50 (2.0, 6.5) 4.50 (2.0, 6.5) 4.50 (2.0, 6.5) 
25’TWT score (seconds) 
Mean (SD) 9.05 (5.61) 9.09 (7.62) 9.08 (6.87) 
Median (range) 
7.23  
(3.7, 41.0) 
6.90  
(3.1, 117.7) 
7.05  
(3.1, 117.7) 
9-HPT score *(seconds) 
Mean (SD) 28.44 (11.47) 28.79 (16.45) 28.65 (14.62) 
Median (range) 
25.26  
(17.2, 115.8) 
25.33  
(13.9, 218.3) 
25.28  
(13.9, 218.3) 
PASAT 3 score 
Mean (SD) 44.3 (13.0) 45.0 (12.5)  
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Median (range) 48.0 (4, 60) 48.0 (0, 60)  
History of DMT use, n (%) 
Treatment naïve  272 (81.0%)   372 (76.4%)   644 (78.3%) 
Any IFN β 36 (10.7%)     66 (13.6%)    102 (12.4%) 
Natalizumab 3 (0.9%)     2 (0.4%)      5 (0.6%) 
Glatiramer acetate 26 (7.7%)     33 (6.8%)     59 (7.2%) 
Other MS medicines 19 (5.7%)     36 (7.4%)     54 (6.7%) 
MRI characteristics 
Number of Gd-enhancing lesions  
N 336 484 820 
Mean (SD) 0.3 (1.10) 0.3 (1.03) 0.3 (1.06) 
Median (range)  0 (0, 10) 0 (0, 14) 0 (0, 14) 
n, (%) free of Gd+  290 (86.3) 423 (87.4) 713 (87.0) 
Total volume of T2 lesions (mm3) 
N 336 485 821 
Mean (SD) 
9442.7  
(10179.7) 
10038.2 
(13030.9) 
9794.5 (11943.5) 
Median (range) 
6109.5 
(145, 52484) 
5271.0 
(44, 91964) 
5705.0  
(44,  91964 ) 
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*Dominant hand 
 
Normalised brain volume (cm3) 
N 335 483 818 
Mean (SD) 1490.9 (86.5) 1491.7 (84.9) 1491.4 (85.5) 
Median (range) 1491.0 (1243, 1725) 1498.0 (1206, 1725) 1493.0 (1206, 1725) 
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Table 2. Efficacy analysis for primary and secondary endpoints 
Primary endpoint: 3-month confirmed disability progression (composite) 
 % progression  
(95% CI)* 
% risk 
reduction 
Hazard ratio  
(95% CI)† 
p-value 
Fingolimod 0.5 mg 
(n=336) 
77.2%  
(71.87, 82.51) 
5.05% 0.95 (0.80, 1.12) 0.544 
Placebo 
(n=487) 
80.3%  
(73.31, 87.25) 
3-month confirmed disability progression (EDSS)  
 % progression  
(95% CI)* 
% risk 
reduction 
Hazard ratio  
(95% CI)† 
p-value 
Fingolimod 0.5 mg 
(n=336) 
54.3%  
(47.16, 61.45) 
11.99% 0.88 (0.72, 1.08) 0.217 
Placebo 
(n=487) 
58.7%  
(53.30, 64.18) 
3-month confirmed disability progression (9-HPT) 
 % progression  
(95% CI)* 
% risk 
reduction 
Hazard ratio  
(95% CI)† 
p-value 
Fingolimod 0.5 mg 
(n=336) 
33.6% 
(26.11, 41.08) 
6.94% 0.93 (0.71, 1.22) 0.607 
Placebo 
(n=487) 
41.3% 
(32.10, 50.55) 
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3-month confirmed disability progression (25’TWT) 
 % progression  
(95% CI)* 
% risk 
reduction 
Hazard ratio  
(95% CI)† 
p-value 
Fingolimod 0.5 mg 
(n=336) 
62.9% 
(57.10, 68.62)   
5.59% 0.94 (0.78, 1.14) 0.546 
Placebo 
(n=487) 
70.0% 
(61.78, 78.21)   
Percent change in brain volume to Month 36 
 Adjusted mean 
(95% CI)  
Adjusted mean difference 
(95% CI) ‡ 
p-value 
Fingolimod 0.5 mg 
(n=293) 
‒1.49 
(‒1.64, ‒1.35) 0.04 
(‒0.15, 0.23) 
0.673 
Placebo 
(n=421) 
‒1.53 
(‒1.65, ‒1.41) 
Number of new/newly enlarged T2 lesions to Month 36 
 Adjusted mean 
(95% CI)§ 
Rate reduction 
(%) 
Rate ratio 
(95% CI)§ 
p-value 
Fingolimod 0.5 mg 
(n=298) 
0.13/year 
(0.10, 0.18) 73.3 
0.267  
(0.185, 0.386) 
<0.001 
Placebo 0.50/year 
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(n=431) (0.40, 0.61) 
Proportion of patients free of new/newly enlarging T2 lesions to end of study 
 Proportion  Odds ratio (95% CI)
†† p-value 
Fingolimod 0.5 mg 
(n=298) 
79.9% 
2.79 (1.95, 4.00) <0.001 
Placebo 
(n=431) 
60.3% 
Number of Gd-enhancing T1 lesions at Month 36 
 Adjusted mean 
(95% CI)§ 
Rate reduction 
(%) 
Rate ratio 
(95% CI)§ 
p-value 
Fingolimod 0.5 mg 
(n=223) 
0.05 
(0.02, 0.09) 
78.3% 
0.217   
(0.102, 0.463)     
<0.001 
Placebo 
(n=320) 
0.21 
(0.15, 0.30)  
Proportion of patients free of Gd-enhancing T1 lesions to end of study 
 Proportion  Odds ratio (95% CI)
¶ p-value 
Fingolimod 0.5 mg 
(n=299) 
87.0% 
2.15 (1.39, 3.33) <0.001 
Placebo 
(n=432) 
77.5% 
CI: confidence interval; n=total number of patients included in the analysis. 
*Estimated from Kaplan-Meier analysis (for the end of study).  
†Time to event using a Cox regression model adjusted for treatment, region, baseline EDSS, baseline 
25’TWT, baseline 9-HPT for the composite endpoint (baseline EDSS, baseline 9-HPT and baseline 25’TWT 
for these respective parameters) and age. 
Page 27 of 33 
 
‡ Obtained from fitting a random coefficients model with treatment and region as fixed effects; and 
time, baseline number of Gd-enhancing T1 lesions, baseline T2 volume, and baseline normalised brain 
volume as continuous covariates. 
§Obtained from fitting a negative binomial regression model adjusted for treatment, region, baseline 
number of Gd-enhanced T1 lesions, and age. 
††Obtained from fitting a logistic regression model adjusted for treatment, region, baseline number of                  
Gd-enhanced T1 lesions and age.  
¶Obtained from fitting a logistic regression model adjusted for treatment, region, and age.                             
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Table 3. Adverse events, according to study group. 
 
Event 
Fingolimod 
0.5 mg 
(N=336) 
Placebo 
(N=487) 
All events, n (%) 
At least one adverse event 324 (96.4%) 463 (95.1%) 
Any adverse event leading to discontinuation of study 
drug* 
52 (15.5%) 36 (7.4%) 
Any serious adverse event 84 (25.0%) 117 (24.0%) 
Abnormal laboratory value leading to discontinuation 
of study drug 
27 (8.0%) 6 (1.2%) 
Death 1 (0.3%) 2 (0.4%) 
Most common AEs (≥5% in any group, preferred term), n (%) 
Nasopharyngitis 78 (23.2%) 135 (27.7%) 
Headache 56 (16.7%) 77 (15.8%) 
Urinary tract infection 50 (14.9%) 79 (16.2%) 
Fall 47 (14.0%) 94 (19.3%) 
Hypertension 43 (12.8%) 28 (5.7%) 
Alanine aminotransferase increased 39 (11.6%) 9 (1.8%) 
Back pain 37 (11.0%) 75 (15.4%) 
Upper respiratory tract infection 37 (11.0%) 58 (11.9%) 
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Gamma-glutamyltransferase increased 31 (9.2%) 3 (0.6%) 
Arthralgia 30 (8.9%) 49 (10.1%) 
Constipation 29 (8.6%) 36 (7.4%) 
Influenza 29 (8.6%) 43 (8.8%) 
Cough 28 (8.3%) 34 (7.0%) 
Fatigue 25 (7.4%) 44 (9.0%) 
Nausea 21 (6.3%) 19 (3.9%) 
Pain in extremity 21 (6.3%) 36 (7.4%) 
Dizziness 19 (5.7%) 29 (6.0%) 
Lymphopenia 19 (5.7%) 0 (0.0%) 
Pyrexia 18 (5.4%) 21 (4.3%) 
Abdominal pain upper 17 (5.1%) 12 (2.5%) 
Melanocytic naevus 16 (4.8%) 31 (6.4%) 
Depression 15 (4.5%) 39 (8.0%) 
Insomnia 12 (3.6%) 29 (6.0%) 
Adverse events of special interest, n (%) 
Cardiovascular disorders   
Bradycardia 5 (1.5%) 1 (0.2%) 
Sinus Bradycardia 0 0 
AV block first degree 3 (0.9%) 6 (1.2%) 
AV block second degree 1 (0.3%) 0 
Myocardial infarction 1 (0.3%) 0 
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Myocardial ischemia 1 (0.3%) 0 
Angina pectoris 1 (0.3%) 3 (0.6%) 
Hypertensive crisis 0 1 (0.2%) 
Secondary hypertension 1 (0.3%) 0 
Hypotension 2 (0.6%) 5 (1.0%) 
Syncope / Presyncope 7 (2.1%) 9 (1.8%) 
Macular Oedema    
Macular Oedema 6 (1.8%) 6 (1.2%) 
Cystoid ME 1 (0.3%) 1 (0.2%) 
Infection and Infestations   
Bronchitis  16 (4.8%) 21 (4.3%) 
Cystitis/bacterial  9 (2.7%) 19 (3.9%) 
Tinea versicolour  6 (1.8%) 8 (1.6%) 
Pneumonia/Bronchopneumonia 6 (1.8%) 8 (1.6%) 
Rare Infection and Infestations   
Meningitis 0 1 (0.2%) 
Systemic mycosis  1 (0.3%) 0 
Pulmonary sepsis 0 1 (0.2%) 
Urosepsis 0 2 (0.4%) 
Serratia sepsis 0 1 (0.2%) 
Herpes zoster/VZV   
Herpes Zoster 10 (3.0%) 9 (1.8%) 
Herpes Zoster meningomyelitis 1 (0.3%)  0 
Herpes zoster neurological 0 1 (0.2%) 
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Herpes Zoster oticus/ophthalmic 0 1 (0.2%) 
Hepatobiliary disorders   
Hepatocellular injury 2 (0.6%) 0 
Hepatic function abnormal 1 (0.3%) 1 (0.2%) 
Hyperbilirubinaemia 1 (0.3%) 0 
Skin cancer   
Basal cell carcinoma 14 (4.2%) 9 (1.8%) 
Squamous cell carcinoma/of skin (comb.) 6 (1.8%) 1 (0.2%) 
Malignant melanoma/ in situ (comb.) 1 (0.3%) 0 
Other malignancies   
Breast cancer 1 (0.3%) 0 
Invasive lobular breast carcinoma 0 1 (0.2%) 
Non-Hodgkin‘s lymphoma 1 (0.3%) 0 
Lung neoplasm malignant 1 (0.3%) 0 
Ovarian cancer 1 (0.3%) 0 
Prostate cancer 1 (0.3%) 1 (0.2%) 
Respiratory   
Dyspnoea 14 (4.2%) 16 (3.3%) 
(exertional) 0 5 (1.0%) 
Seizures/Convulsions   
Convulsion 2 (0.6%) 2 (0.4%) 
Epilepsy 1 (0.3%) 0 
Status epilepticus 0 1 (0.2%) 
Page 32 of 33 
 
Investigations   
Blood cholesterol increased 15 (4.5%) 16 (3.3%) 
Blood triglycerides increased 9 (2.7%) 9 (1.8%) 
Low density lipoprotein increased 7 (2.1%) 3 (0.6%) 
Weight increased 5 (1.5%) 1 (0.2%) 
Carbon monoxide diffusing capacity decreased 7 (2.1%) 8 (1.6%) 
*Any adverse event leading to discontinuation of the study drug includes events occurring in patients 
whose primary or secondary reason for discontinuing the study drug was an adverse event (including 
abnormal laboratory findings). 
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Figure legends 
Figure 1. Enrolment, randomization, and follow-up  
AE, adverse event 
 
Figure 2. Time to 3-month confirmed disability progression: (A) primary composite endpoint; (B) EDSS 
(key secondary endpoint) 
 HR: hazard ratio; CI: confidence interval 
 
